GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2-endocrine sensitive advanced breast cancer (ABC)

Albanell, J.Martinez, M. T. M.Ramos, M.O'Connor, M.De la Cruz-Merino, L.Santaballa Bertran, A.Martinez-Janez, N.Moreno, F.Fernandez Perez, I.Alarcon Company, J.Virizuela Echaburu, J. A.De la Haba Rodriguez, J.Sanchez-Rovira, P.Gonzalez-Cortijo, L.Margeli Vila, M.Sanchez Munoz, A.Garau Llinas, I.Casas, M.Bezares Montes, S.Rojo Todo, F.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/25918enGEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2-endocrine sensitive advanced breast cancer (ABC)conference outputopen access10.1016/j.annonc.2020.08.22471569-8041http://www.annalsofoncology.org/article/S0923753420423294/pdf573469102645